Neurizon Therapeutics (ASX:NUZ) clinical-stage biotechnology company developing new therapeutics for neurodegenerative diseases. The Company’s lead pipeline indication is targeting amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND).
Neurizon has an extensive patent portfolio with multiple ‘methods of use’ patents granted and filed covering the use of NUZ-001 for the treatment of neurodegenerative diseases. The Company successfully completed a Phase 1 study of NUZ-001 in patients with ALS/MND with encouraging and robust results. At present, Neurizon anticipates commencing the following Phase 2/3 study in Q1 CY25.
The Company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited on 15 Oct 2024. The Company was listed on the ASX in Oct 2001.